New Triple-Threat attack on tough brain cancer
NCT ID NCT04421560
Summary
This study is testing a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) for adults with primary central nervous system lymphoma (PCNSL) that has returned or not responded to prior treatment. The goal is to see if this combination can control the cancer and stop it from growing for a longer period. The study will first check the safety of the combination and then see how well it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Columbia University Medical Center
WITHDRAWNNew York, New York, 10032, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
Conditions
Explore the condition pages connected to this study.